A Phase 3 interventional study of Aumolertinib monotherapy and Osimertinib monotherapy in NSCLC, sponsored by EQRx International, Inc.. Terminated at 8 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-02.
Sponsored by EQRx International, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Aumolertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that targets EGFR mutations. The reason for this study is to learn whether adding chemotherapy to a new investigational drug called aumolertinib helps to slow or stop cancer growth in people with EGFR mutation-positive, locally advanced or metastatic non-small cell lung cancer (NSCLC). The study will compare this new combination of drugs to osimertinib, given alone. Aumolertinib given alone will also be used in the study, and it will be looked at in comparison with osimertinib given alone.
This is a randomized, open-label study with 3 different groups that are listed below. "Randomized" means the study treatment participants take will be chosen by chance (decided at random by a computer). "Open-label" means that the participant, the study doctor, and the Sponsor will know which study treatment each participant is receiving.
Participants will be randomly assigned to one of the following 3 treatment groups:
Because there will be twice as many participants in Group 2 and Group 3 as in Group 1, the chance of a participant being randomly assigned to either of those groups is twice as likely as being assigned to Group 1.
Participants can continue to receive study treatment as long as they have not withdrawn consent, as long as they choose to continue to receive study treatment and are judged by their doctor to continue to receive clinical benefit from receiving the study treatment, and as long as no other study treatment and/or study discontinuation criteria are met .
EQRx International, Inc. is the lead sponsor of 4 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Aumolertinib monotherapy
For adenocarcinoma, either: * Aumolertinib + cisplatin with pemetrexed, or * Aumolertinib + carboplatin with pemetrexed For squamous cell carcinoma, one of the following: * Aumolertinib + cisplatin or carboplatin with paclitaxel; * Aumolertinib + cisplatin or carboplatin with albumin-bound paclitaxel; or * Aumolertinib + cisplatin or carboplatin with gemcitabine
Drug: Aumolertinib monotherapy · Drug: Pemetrexed · Drug: Cisplatin · Drug: Carboplatin · Drug: Paclitaxel · Drug: Nab paclitaxel · Drug: Gemcitabine
Drug: Osimertinib monotherapy
Administered orally, once daily as two 55-mg tablets for a total dose of 110 mg.
Also known as: EQ143, HS-10296
80 mg tablet administered orally, once daily
Also known as: Tagrisso
Administered by IV Infusion per prescribing information. Maybe be continued as maintenance therapy
Also known as: Alimta
Administered by IV Infusion given over 4 fixed cycles (q3wk × 4 cycles) per prescribing information.
Administered by IV Infusion given over 4 fixed cycles (q3wk × 4 cycles) per prescribing information.
Administered by IV Infusion given over 4 -6 fixed cycles per prescribing information.
Also known as: Taxol
Administered by IV Infusion given over 4 fixed cycles per prescribing information.
Also known as: Abraxane, Albumin-bound paclitaxel
Administered by IV Infusion over 4 fixed cycles per prescribing information.
Also known as: Gemzar
This study also gives Osimertinib. No intervention listed here names it: that was found by reading the record.
Progression Free Survival (PFS) as Assessed by Blinded Independent Central Review (BICR) Per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
PFS is defined as the time from date of randomization until date of disease progression or death due to any cause, whichever occurs first.
Time frame: Up to 5 years
Overall Survival (OS)
OS is defined as the time from date of randomization until death from any cause.
Time frame: Up to 6 years
Objective Response Rate (ORR) as Assessed by BICR Per RECIST v1.1
ORR is defined as proportion of participants who achieve a complete response or partial response at any time before progressive disease or initiating a subsequent anticancer therapy.
Time frame: Up to 5 years
Disease Control Rate (DCR) as Assessed by BICR Per RECIST v1.1
DCR is defined as the proportion of participants who have a best overall response of complete response or partial response or stable disease.
Time frame: Up to 5 years
Tumor Growth Rate (TGR) as Assessed by BICR Per RECIST v1.1
TGR is defined as the constant exponential growth rate estimated using the sum of longest diameters based on radiological tumor assessment per RECIST v1.1.
Time frame: Up to 5 years
Duration of Response (DOR) as Assessed by BICR Per RECIST v1.1
DOR is defined as date of first response (complete response or partial response) until date of disease progression or death due to any cause, whichever occurs first
Time frame: Up to 5 years
Depth of Response (DepOR) as Assessed by BICR Per RECIST v1.1
DepOR is defined as the relative change in target lesion tumor size (calculated as the sum of the longest diameters of the target lesions, in the absence of new lesions or progression of nontarget lesions) as compared to baseline.
Time frame: Up to 5 years
PFS as Assessed by the Investigator Per RECIST v1.1
PFS is defined as the time from date of randomization until date of disease progression or death due to any cause, whichever occurs first.
Time frame: Up to 5 years
ORR as Assessed by the Investigator Per RECIST v1.1
ORR is defined as the proportion of participants who achieve a complete response or partial response at any time before disease progression or initiating a subsequent anticancer therapy.
Time frame: Up to 5 years
DCR as Assessed by the Investigator Per RECIST v1.1
DCR is defined as the proportion of participants who have a best overall response of complete response or partial response or stable disease.
Time frame: Up to 5 years
TGR as Assessed by the Investigator Per RECIST v1.1
TGR is defined as the constant exponential growth rate estimated using the sum of longest diameters based on radiological tumor assessment per RECIST v1.1.
Time frame: Up to 5 years
DOR as Assessed by the Investigator Per RECIST v1.1
DOR is defined as date of first response (complete response or partial response) until the date of disease progression or death due to any cause, whichever occurs first.
Time frame: Up to 5 years
DepOR as Assessed by the Investigator Per RECIST v1.1
DepOR is defined as the relative change in target lesion tumor size (calculated as the sum of the longest diameters of the target lesions, in the absence of new lesions or progression of nontarget lesions) as compared to baseline.
Time frame: Up to 5 years
Quality of Life as Assessed by the National Cancer Institute Patient Reported Outcomes Common Terminology Criteria for Adverse Events (NCI PRO-CTCAE) Questionnaire
NCI PRO-CTCAE questionnaire responses are scored from 0 to 4, wherein lower values represent a better outcome. For this trial, the burden of symptoms that will be captured by this questionnaire comprises nausea, diarrhea, and rash.
Time frame: Up to 5 years
Rate of Circulating Tumor DNA (ctDNA) Clearance
ctDNA clearance is defined as when a detectable EGFR mutation in ctDNA at baseline becomes undetectable or drops below a predetermined threshold. Rate of ctDNA clearance is defined as 100 × number of participants who are ctDNA-negative at 6 weeks divided by number of participants who are ctDNA-positive at baseline.
Time frame: 6 weeks
Plasma Concentration of Aumolertinib
Plasma concentration is defined as the measured drug concentration of aumolertinib.
Time frame: Up to approximately 5 months
Plasma Concentration of Aumolertinib Metabolite
Plasma concentration is defined as the measured drug concentration of aumolertinib metabolite.
Time frame: Up to approximately 5 months
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
This outcome will evaluate the incidence of participants with TEAEs, graded according to NCI CTCAE V5.
Time frame: From date of treatment initiation until discontinuation from treatment (plus 28 days for TEAEs), up to 5 years
Number of Participants With Serious Adverse Events (SAEs)
This outcome will evaluate incidence of participants with SAEs, be graded according to NCI CTCAE V5.
Time frame: From date of treatment initiation until discontinuation from treatment (plus 28 days for TEAEs), up to 5 years
Number of Participants With Electrocardiogram (ECG) Abnormalities
This outcome will evaluate incidence of participants with ECG abnormalities
Time frame: From date of treatment initiation until discontinuation from treatment (plus 28 days for TEAEs), up to 5 years
Number of Participants With Laboratory Abnormalities
This outcome will evaluate incidence of participants with laboratory abnormalities, graded according to NCI CTCAE V5.
Time frame: From date of treatment initiation until discontinuation from treatment (plus 28 days for TEAEs), up to 5 years
| Milestone | Aumolertinib Monotherapy | Aumolertinib + Platinum-based Doublet Chemotherapy | Osimertinib Monotherapy |
|---|---|---|---|
| Started | 1 | 2 | 5 |
| Completed | 0 | 0 | 0 |
| Not completed | 1 | 2 | 5 |
PFS is defined as the time from date of randomization until date of disease progression or death due to any cause, whichever occurs first.
No measurements were reported for this outcome.
OS is defined as the time from date of randomization until death from any cause.
No measurements were reported for this outcome.
ORR is defined as proportion of participants who achieve a complete response or partial response at any time before progressive disease or initiating a subsequent anticancer therapy.
No measurements were reported for this outcome.
DCR is defined as the proportion of participants who have a best overall response of complete response or partial response or stable disease.
No measurements were reported for this outcome.
TGR is defined as the constant exponential growth rate estimated using the sum of longest diameters based on radiological tumor assessment per RECIST v1.1.
No measurements were reported for this outcome.
DOR is defined as date of first response (complete response or partial response) until date of disease progression or death due to any cause, whichever occurs first
No measurements were reported for this outcome.
DepOR is defined as the relative change in target lesion tumor size (calculated as the sum of the longest diameters of the target lesions, in the absence of new lesions or progression of nontarget lesions) as compared to baseline.
No measurements were reported for this outcome.
PFS is defined as the time from date of randomization until date of disease progression or death due to any cause, whichever occurs first.
No measurements were reported for this outcome.
ORR is defined as the proportion of participants who achieve a complete response or partial response at any time before disease progression or initiating a subsequent anticancer therapy.
No measurements were reported for this outcome.
DCR is defined as the proportion of participants who have a best overall response of complete response or partial response or stable disease.
No measurements were reported for this outcome.
TGR is defined as the constant exponential growth rate estimated using the sum of longest diameters based on radiological tumor assessment per RECIST v1.1.
No measurements were reported for this outcome.
DOR is defined as date of first response (complete response or partial response) until the date of disease progression or death due to any cause, whichever occurs first.
No measurements were reported for this outcome.
DepOR is defined as the relative change in target lesion tumor size (calculated as the sum of the longest diameters of the target lesions, in the absence of new lesions or progression of nontarget lesions) as compared to baseline.
No measurements were reported for this outcome.
NCI PRO-CTCAE questionnaire responses are scored from 0 to 4, wherein lower values represent a better outcome. For this trial, the burden of symptoms that will be captured by this questionnaire comprises nausea, diarrhea, and rash.
No measurements were reported for this outcome.
ctDNA clearance is defined as when a detectable EGFR mutation in ctDNA at baseline becomes undetectable or drops below a predetermined threshold. Rate of ctDNA clearance is defined as 100 × number of participants who are ctDNA-negative at 6 weeks divided by number of participants who are ctDNA-positive at baseline.
No measurements were reported for this outcome.
Plasma concentration is defined as the measured drug concentration of aumolertinib.
No measurements were reported for this outcome.
Plasma concentration is defined as the measured drug concentration of aumolertinib metabolite.
No measurements were reported for this outcome.
This outcome will evaluate the incidence of participants with TEAEs, graded according to NCI CTCAE V5.
No measurements were reported for this outcome.
This outcome will evaluate incidence of participants with SAEs, be graded according to NCI CTCAE V5.
No measurements were reported for this outcome.
This outcome will evaluate incidence of participants with ECG abnormalities
No measurements were reported for this outcome.
This outcome will evaluate incidence of participants with laboratory abnormalities, graded according to NCI CTCAE V5.
No measurements were reported for this outcome.
Collected over Adverse events were collected until the study reached early termination. Adverse events were collected from date of treatment initiation until discontinuation from treatment (plus 28 days for TEAEs), approximately 8 months, 17 days.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Aumolertinib Monotherapy | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) |
| Aumolertinib + Platinum-based Doublet Chemotherapy | 0/2 (0%) | 0/2 (0%) | 2/2 (100%) |
| Osimertinib Monotherapy | 0/5 (0%) | 0/5 (0%) | 5/5 (100%) |
| Event | Aumolertinib Monotherapy | Aumolertinib + Platinum-based Doublet Chemotherapy | Osimertinib Monotherapy |
|---|---|---|---|
| Abdominal pain upperGastrointestinal disorders | 0/1 | 2/2 | 0/5 |
| DiarrhoeaGastrointestinal disorders | 1/1 | 0/2 | 3/5 |
| NauseaGastrointestinal disorders | 1/1 | 2/2 | 1/5 |
| FatigueGeneral disorders | 0/1 | 2/2 | 1/5 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 1/1 | 0/2 | 0/5 |
| Dermatitis acneiformSkin and subcutaneous tissue disorders | 1/1 | 0/2 | 0/5 |
| Gastro-oesophageal reflux diseaseGastrointestinal disorders | 0/1 | 1/2 | 0/5 |
| VomitingGastrointestinal disorders | 0/1 | 1/2 | 0/5 |
| Neutrophil count decreasedInvestigations | 0/1 | 1/2 | 1/5 |
| Muscular weaknessMusculoskeletal and connective tissue disorders | 0/1 | 1/2 | 0/5 |
Study terminated early, no participants completed the study, no participants were analyzed.
| Age, Continuous(years) | Aumolertinib Monotherapy | Aumolertinib + Platinum-based Doublet Chemotherapy | Osimertinib Monotherapy | Total |
|---|---|---|---|---|
| Mean | 69 (69 to 69) | 71 (66 to 75) | 63 (52 to 74) | 66 (52 to 75) |
| Sex: Female, Male(Participants) | Aumolertinib Monotherapy | Aumolertinib + Platinum-based Doublet Chemotherapy | Osimertinib Monotherapy | Total |
|---|---|---|---|---|
| Female | 1 | 2 | 4 | 7 |
| Male | 0 | 0 | 1 | 1 |
| Ethnicity (NIH/OMB)(Participants) | Aumolertinib Monotherapy | Aumolertinib + Platinum-based Doublet Chemotherapy | Osimertinib Monotherapy | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 1 | 1 |
| Not Hispanic or Latino | 1 | 2 | 4 | 7 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Aumolertinib Monotherapy | Aumolertinib + Platinum-based Doublet Chemotherapy | Osimertinib Monotherapy | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 1 | 2 | 5 | 8 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Dec 2022 to primary completion in Aug 2023, 8 months.
Results were first posted in May 2024, 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aumolertinib
EQRx International, Inc.